Issued on behalf of AVAI Bio, Inc. LAS VEGAS, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - Type 1 diabetes has an ...
Two abstracts selected for oral presentations, highlighting investigational CAR-NK cell therapy’s clinical activity in idiopathic inflammatory ...
UCLA researchers have developed a way to mass-produce cancer-fighting T cells from blood stem cells found in cord blood, ...
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease of the central nervous system in which the immune ...
Etentamig and the Next Wave of Immune Engagers in Multiple Myeloma / cancer, CERVINO Trial, Cevostamab, Dual-Antigen ...
Results show that eliminating dendritic cells from the lymph nodes wiped out elevated levels of T cells in mice, and slowed cognitive decline.
IND clearance enables U.S. clinical development of KT501, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager for B cell–mediated autoimmune diseases, ...
Cases of immune-mediated inflammatory diseases (IMIDs) such as type 1 diabetes and asthma, have been rising in the last two ...
T-cell redirecting platforms function by enabling antigen-specific recognition or by colocalizing effector T cells with tumor ...
Novartis has halted eight trials of its cellular therapy rapcabtagene autoleucel in patients with rheumatic and neurological ...
Obesity appears to leave a molecular imprint on key immune cells that may persist for 5 to 10 years after weight loss. This long-lasting “obesity memory” could help explain why some obesity-related ...
The 2026 IPO streak continues as Electra Therapeutics has filed to go public to support its immunology and cancer pipeline. | ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results